An Escalating Dose Phase IIa Study of L-Asparaginase Encapsulated in Erythrocytes (GRASPA) in Association With Polychemotherapy During Induction Phase for Treatment of Elderly Patients With Acute Lymphoblastic Leukaemia (ALL), Aged 55 Years and Over, With Philadelphia Chromosome-negative (ALL Ph-)

Trial Profile

An Escalating Dose Phase IIa Study of L-Asparaginase Encapsulated in Erythrocytes (GRASPA) in Association With Polychemotherapy During Induction Phase for Treatment of Elderly Patients With Acute Lymphoblastic Leukaemia (ALL), Aged 55 Years and Over, With Philadelphia Chromosome-negative (ALL Ph-)

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs ERY-ASP (Primary) ; Antineoplastics
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors ERYtech Pharma
  • Most Recent Events

    • 20 Oct 2015 Results published in the September 2015 issue of the American Journal of Hematology, according to an ERYtech Pharma media release.
    • 17 Jun 2012 Results were presented at the 17th Congress of the European Haematology Association (EHA-2012), according to an ERYtech Pharma media release.
    • 02 Feb 2012 Primary and Secondary outcomes identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top